1. Home
  2. AIMD vs PRPO Comparison

AIMD vs PRPO Comparison

Compare AIMD & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIMD

Ainos Inc.

HOLD

Current Price

$2.01

Market Cap

10.2M

Sector

Health Care

ML Signal

HOLD

Logo Precipio Inc.

PRPO

Precipio Inc.

HOLD

Current Price

$23.29

Market Cap

32.4M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIMD
PRPO
Founded
1984
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
10.2M
32.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AIMD
PRPO
Price
$2.01
$23.29
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
28.0K
10.1K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$113,037.00
$22,800,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
178.19
30.95
52 Week Low
$1.78
$3.90
52 Week High
$5.00
$28.50

Technical Indicators

Market Signals
Indicator
AIMD
PRPO
Relative Strength Index (RSI) 39.33 51.92
Support Level $1.94 $22.10
Resistance Level $2.18 $25.03
Average True Range (ATR) 0.14 1.29
MACD 0.03 -0.29
Stochastic Oscillator 15.68 41.28

Price Performance

Historical Comparison
AIMD
PRPO

About AIMD Ainos Inc.

Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: